In addition, minocycline (5, 8) or antibodies directed against tumour necrosis factor-alpha (TNF-α) (10) can be used to block microglial activation (11) in experimental glaucoma models, prevent immune cell infiltration, and significantly reduce RGC death. The gene discussed is TNF; the disease is glaucoma.